美国 · SEC FORM 4
Opus Genetics, Inc.
IRD · Nasdaq · CIK 0001228627 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
16 同一窗口内观察到的 Form 4 交易行
13 sales · 3 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-29 · Gallagher Cam.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 13,013,222
- 上期报告
- 12,578,772
- 日均成交量
- 2,150,972
- 回补天数
- 6.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | Gallagher Cam | 买入 (P) | Common Stock | 164,000 | USD 1.97 | USD 323,890 | SEC 申报 ↗ |
| 2024-12-26 | Magrath George | 买入 (P) | Common Stock | 100,000 | USD 0.98 | USD 98,000 | SEC 申报 ↗ |
| 2024-11-21 | YERXA BENJAMIN R | 买入 (P) | Common Stock | 10,000 | USD 0.98 | USD 9,800 | SEC 申报 ↗ |
| 2024-11-18 | Magrath George | 买入 (P) | Common Stock | 9,706 | USD 1.02 | USD 9,900 | SEC 申报 ↗ |
| 2024-11-15 | Magrath George | 买入 (P) | Common Stock | 90,294 | USD 1.01 | USD 91,197 | SEC 申报 ↗ |
| 2024-05-22 | Jayagopal Ashwath | 买入 (P) | Common Stock | 3,500 | USD 1.77 | USD 6,195 | SEC 申报 ↗ |
| 2024-05-17 | Magrath George | 买入 (P) | Common Stock | 5,000 | USD 1.75 | USD 8,750 | SEC 申报 ↗ |
| 2024-03-21 | SCHACHLE JOSEPH K | 买入 (P) | Common Stock | 2,000 | USD 2.05 | USD 4,100 | SEC 申报 ↗ |
| 2024-03-21 | Jhaveri Nirav S. | 买入 (P) | Common Stock | 10,000 | USD 2.10 | USD 21,000 | SEC 申报 ↗ |
| 2024-03-18 | Magrath George | 买入 (P) | Common Stock | 25,000 | USD 1.96 | USD 49,000 | SEC 申报 ↗ |
| 2022-05-20 | MANUSO JAMES S J | 买入 (P) | Common Stock | 5,000 | USD 1.99 | USD 9,950 | SEC 申报 ↗ |
| 2022-05-20 | Sooch Mina | 买入 (P) | Common Stock | 12,500 | USD 2.02 | USD 25,250 | SEC 申报 ↗ |
| 2022-05-19 | Sooch Mina | 买入 (P) | Common Stock | 12,500 | USD 2.07 | USD 25,875 | SEC 申报 ↗ |
| 2021-12-13 | Pepose Jay | 买入 (P) | Common Stock | 8,250 | USD 3.65 | USD 30,112 | SEC 申报 ↗ |
| 2021-11-18 | MANUSO JAMES S J | 买入 (P) | Common Stock | 2,000 | USD 3.50 | USD 7,000 | SEC 申报 ↗ |
Form 4 申报证据
48 transaction lines in the latest 365-day window; 171 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund; Foundation Fighting Blindness, Inc. | 卖出 (S) | Common Stock | 556,000 | USD 4.96 | USD 2,755,981 | SEC 申报 ↗ |
| 2026-09-09 | Magrath George | 期权行权／转换 (M) | Common Stock | 392,157 | USD 1.15 | USD 450,981 | SEC 申报 ↗ |
| 2026-09-09 | Magrath George | 代扣税 (F) | Common Stock | 75,541 | USD 5.97 | USD 450,980 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund; Foundation Fighting Blindness, Inc. | 卖出 (S) | Common Stock | 556,000 | USD 4.96 | USD 2,755,981 | SEC 申报 ↗ |
| 2026-09-09 | Magrath George | 期权行权／转换 (M) | Common Stock | 392,157 | USD 1.15 | USD 450,981 | SEC 申报 ↗ |
| 2026-09-09 | Magrath George | 代扣税 (F) | Common Stock | 75,541 | USD 5.97 | USD 450,980 | SEC 申报 ↗ |
| 2026-09-08 | Gallagher Cam | 期权行权／转换 (M) | Common Stock | 784,314 | USD 1.15 | USD 901,961 | SEC 申报 ↗ |
| 2026-09-03 | Gagnon Robert E. | 卖出 (S) | Common Stock | 28,000 | USD 4.54 | USD 127,120 | SEC 申报 ↗ |
| 2026-07-23 | YERXA BENJAMIN R | 卖出 (S) | Common Stock | 7,429 | USD 2.97 | USD 22,064 | SEC 申报 ↗ |
| 2026-07-23 | SCHACHLE JOSEPH K | 卖出 (S) | Common Stock | 4,644 | USD 2.94 | USD 13,653 | SEC 申报 ↗ |
| 2026-07-23 | Magrath George | 卖出 (S) | Common Stock | 9,475 | USD 2.95 | USD 27,951 | SEC 申报 ↗ |
| 2026-07-23 | Gagnon Robert E. | 卖出 (S) | Common Stock | 7,783 | USD 2.95 | USD 22,960 | SEC 申报 ↗ |
| 2026-05-18 | Foundation Fighting Blindness Retinal Degeneration Fund; Foundation Fighting Blindness, Inc. | 卖出 (S) | Common Stock | 1,700,000 | USD 4.35 | USD 7,395,000 | SEC 申报 ↗ |
| 2026-04-23 | Zaremba Rabourn Amy | 卖出 (S) | Common Stock | 1,641 | USD 5.20 | USD 8,533 | SEC 申报 ↗ |
| 2026-04-23 | YERXA BENJAMIN R | 卖出 (S) | Common Stock | 7,470 | USD 5.24 | USD 39,143 | SEC 申报 ↗ |
| 2026-04-23 | SCHACHLE JOSEPH K | 卖出 (S) | Common Stock | 4,697 | USD 5.22 | USD 24,518 | SEC 申报 ↗ |
| 2026-04-23 | Magrath George | 卖出 (S) | Common Stock | 9,511 | USD 5.22 | USD 49,647 | SEC 申报 ↗ |
| 2026-04-23 | Jayagopal Ashwath | 卖出 (S) | Common Stock | 7,542 | USD 5.19 | USD 39,143 | SEC 申报 ↗ |
| 2026-04-23 | Gagnon Robert E. | 卖出 (S) | Common Stock | 7,842 | USD 5.18 | USD 40,622 | SEC 申报 ↗ |
| 2026-04-20 | Rodgers Richard J | 奖励／授予 (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | MANUSO JAMES S J | 奖励／授予 (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Graves Adrienne L | 奖励／授予 (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Gallagher Cam | 奖励／授予 (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Benton Susan | 奖励／授予 (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Bennett Jean | 奖励／授予 (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Ainsworth Sean | 奖励／授予 (A) | Common Stock | 24,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-16 | Zaremba Rabourn Amy | 卖出 (S) | Common Stock | 2,816 | USD 5.25 | USD 14,784 | SEC 申报 ↗ |
| 2026-03-16 | SCHACHLE JOSEPH K | 卖出 (S) | Common Stock | 3,719 | USD 5.25 | USD 19,525 | SEC 申报 ↗ |
| 2026-03-16 | Magrath George | 卖出 (S) | Common Stock | 24,438 | USD 5.21 | USD 127,322 | SEC 申报 ↗ |
| 2026-03-16 | Jayagopal Ashwath | 卖出 (S) | Common Stock | 3,719 | USD 5.12 | USD 19,041 | SEC 申报 ↗ |
| 2026-02-12 | Jayagopal Ashwath | 代扣税 (F) | Common Stock | 5,313 | USD 3.39 | USD 18,011 | SEC 申报 ↗ |
| 2026-01-22 | Zaremba Rabourn Amy | 奖励／授予 (A) | Common Stock | 86,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-22 | YERXA BENJAMIN R | 奖励／授予 (A) | Common Stock | 400,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | IRD |
| CIK | 0001228627 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 171 transaction lines from 2020-11-05 to 2026-09-30 24 P purchase lines · 18 S sale lines · 129 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.